1. Home
  2. BIIB vs WWD Comparison

BIIB vs WWD Comparison

Compare BIIB & WWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIIB
  • WWD
  • Stock Information
  • Founded
  • BIIB 1978
  • WWD 1870
  • Country
  • BIIB United States
  • WWD United States
  • Employees
  • BIIB N/A
  • WWD N/A
  • Industry
  • BIIB Biotechnology: Pharmaceutical Preparations
  • WWD Industrial Machinery/Components
  • Sector
  • BIIB Health Care
  • WWD Energy
  • Exchange
  • BIIB Nasdaq
  • WWD Nasdaq
  • Market Cap
  • BIIB 18.7B
  • WWD 15.5B
  • IPO Year
  • BIIB 1991
  • WWD N/A
  • Fundamental
  • Price
  • BIIB $154.27
  • WWD $262.11
  • Analyst Decision
  • BIIB Buy
  • WWD Strong Buy
  • Analyst Count
  • BIIB 22
  • WWD 10
  • Target Price
  • BIIB $174.11
  • WWD $279.00
  • AVG Volume (30 Days)
  • BIIB 1.5M
  • WWD 462.6K
  • Earning Date
  • BIIB 10-30-2025
  • WWD 11-24-2025
  • Dividend Yield
  • BIIB N/A
  • WWD 0.43%
  • EPS Growth
  • BIIB N/A
  • WWD 5.57
  • EPS
  • BIIB 10.97
  • WWD 6.32
  • Revenue
  • BIIB $10,065,900,000.00
  • WWD $3,426,288,000.00
  • Revenue This Year
  • BIIB $2.03
  • WWD $6.40
  • Revenue Next Year
  • BIIB N/A
  • WWD $9.84
  • P/E Ratio
  • BIIB $14.06
  • WWD $41.49
  • Revenue Growth
  • BIIB 4.77
  • WWD 5.53
  • 52 Week Low
  • BIIB $110.04
  • WWD $146.82
  • 52 Week High
  • BIIB $179.48
  • WWD $270.21
  • Technical
  • Relative Strength Index (RSI)
  • BIIB 64.58
  • WWD 56.84
  • Support Level
  • BIIB $138.00
  • WWD $261.09
  • Resistance Level
  • BIIB $151.91
  • WWD $270.21
  • Average True Range (ATR)
  • BIIB 4.62
  • WWD 7.02
  • MACD
  • BIIB 0.21
  • WWD 0.97
  • Stochastic Oscillator
  • BIIB 94.70
  • WWD 68.14

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

About WWD Woodward Inc.

Woodward Inc is an independent designer, manufacturer, and service provider of control solutions for the aerospace and industrial markets. It designs, produces, and services reliable, efficient, low-emission, and high-performance energy control products for diverse applications in challenging environments. The company operates in two segments, Aerospace and Industrial. The Aerospace segment provides fuel pumps, actuators, air valves, specialty valves, fuel nozzles, and thrust reverser actuation systems for turbine engines and nacelles, and flight deck controls, actuators, servo controls, motors, and sensors for aircraft. The Industrial segment offers actuators, valves, pumps, fuel injection systems, solenoids, ignition systems, speed controls, electronics and software, and sensors.

Share on Social Networks: